Monday, October 20, 2025
25.8 C
Lagos

Europe-Africa Partnership Grants €10m for New Anti-malarial Drug

The European & Developing Countries Clinical Trials Partnership (EDCTP) grants €10 million over five years to “WANECAM 2” a unique collaboration between anti-malarial drug researchers in Africa and Europe from 10 academic institutions, a pharmaceutical company, Novartis, and a not-for-profit product development partnership (PDP), Medicines for Malaria Venture.

The grant will support African trials of a novel anti-malarial combination comprising KAF156 (ganaplacide) and lumefantrine in a new once-daily formulation. KAF156 has demonstrated the potential to treat resistant malaria and to be administered as a single dose; the grant will also help to build and strengthen research capabilities in the four participating African countries: Burkina Faso, Gabon, Mali and Niger.
The European & Developing Countries Clinical Trials Partnership (EDCTP) has granted new funding of €10m over five years to support late-stage clinical trials of a next-generation anti-malarial combination including KAF156 (ganaplacide). The trials will be conducted in four countries in West and Central Africa: Burkina Faso, Gabon, Mali and Niger.
Led by the WANECAM consortium (West African Network for Clinical Trials of Anti-malarial Drugs), ten academic organisations [1] based in Africa and Europe will collaborate with the not-for-profit organization Medicines for Malaria Venture (MMV) and the pharmaceutical company Novartis to develop its compound KAF156 in combination with a new formulation of lumefantrine. The aim is to advance the development of a much-needed new anti-malarial therapy while strengthening clinical trial development capabilities in Africa.
Global partnerships have made significant strides in malaria control over the past 20 years, yet the rate of progress has recently diminished [2]. A recent survey of African malaria leader [3] showed high levels of concern around resistance to some of the current gold-standard treatments, artemisinin combination therapies (ACTs), in Asia, and the likelihood that it could spread to Africa, emphasizing the urgent need for novel, easy-to-administer anti-malarial medicines.
The Principal Investigator, Professor Abdoulaye Djimdé of the L’Université des Sciences, des Techniques et des Technologies de Bamako and coordinator of the WANECAM group, said: “We welcome the generous support from EDCTP and are grateful for their long-term commitment to clinical development in Africa – and specifically supporting clinical research in critical diseases such as malaria. This backing is vital to accelerate the development of this much-needed new compound. African collaboration with a group of international experts on this programme can help ensure the trials are completed rapidly and to the highest quality standards. With reports about parasite resistance to artemisinins and ACTs, it is essential that we have new anti-malarials ready and waiting.”
KAF156 [4], the new anti-malarial compound that will be studied, holds the potential to be the first new chemical class of compound for the treatment of acute malaria in 20 years which in combination with the new formulation of lumefantrine could be administered as a single-dose treatment.

The combination is currently in late-stage clinical trials across 17 centres in nine countries in Africa and Asia. It is being developed by Novartis with scientific and financial support from MMV (in collaboration with the Bill & Melinda Gates Foundation), and is one of seven late-stage anti-malarials being developed by MMV partnerships.

The EDCTP grant will fund two clinical trials for KAF156 in combination with a new formulation of lumefantrine which will include studying its effectiveness in children, the group most at risk of dying from malaria. If successful, data from these trials will support future submissions to register the medicine with regulatory authorities.
The EDCTP funding will also support efforts to strengthen clinical research infrastructure in Niger, as well as existing clinical research capacities at all other trial sites involved. These efforts will involve exchanging experiences and best practices between the sites and the European academic centres, as well as with Novartis and MMV.
Dr. Michael Makanga, EDCTP Executive Director, said: “We are delighted to broaden the coalition of organisations that EDCTP funds and partners to deliver our malaria strategy. By involving the private sector and a not-for-profit PDP, we have broadened our network of expertise. With all sectors working together, we can build stronger partnerships to defeat malaria.”
By 2017, malaria mortality had more than halved in sub-Saharan Africa compared to the turn of the century, due to better prevention, mainly via bednets, and improved treatment with ACTs.

However, over 400,000 people died due to malaria-related causes that year, most of them young children under the age of five.

The most recent 2018 World Malaria Report stated that progress in the fight against the disease is flattening for the second year in a row.

spot_img
spot_img
spot_img

Hot this week

When Transparency Becomes Luxury: INEC and ₦1.5bn FOI Controversy

By Chike Walter Duru When the Independent National Electoral Commission...

Unity Bank Corpreneurship Challenge Beneficiaries Hit 578 as 30 More Winners Emerge

  No fewer than 578 young entrepreneurs across Nigeria have...

Polaris Bank Reinforces Commitment to Exceptional Customer Experience at Global Trade Forum in Ibadan

Chris Ofikulu, Executive Director, Retail & Commercial Banking, Polaris...

Fidelity Bank Bags Awards for Best Export, Trade Support and Innovation

  Fidelity Bank’s market leadership has been affirmed once again...

13-year-old Rhema-Love Abraham Emerges Winner of 2025 Heirs Insurance Essay Championship

L:R- Funmi Olotu, National Coordinator, National Social Safety-Nets Coordinating...

Topics

Sub-saharan Africa, Most Expensive Region for Remittance

Sub-saharan Africa is the most expensive region for sending money inform of remittance from other parts of the world, according to the latest report by the World Bank Group. The report listed South Asia as the least expensive. The World Bank said over $62.5 billion has so far been saved for migrants who send money home to their families in an initiative began in 2005 by the Bank and the international community to reduce the cost of sending money home. Each quarter the World Bank publishes data on how much it costs to send money home.

Bonny Gas Transport Charters Prototype Eco-Friendly Newbuild Vessel, AKTORAS

Mrs. Olu Verheijen, the Special Adviser to the President...

Celebrating 24 Years of Telecom Transformation in Nigeria

By Elvis Eromosele Twenty-four years ago, Nigeria took a giant...

The N200bn ICT Bank, Strategies to Rescue Nigerian Telecom Sector 

By Elvis Eromosele The Nigerian telecommunications sector must have nine...

PenCom: ‘Lack of Foreign Index Bond Impeding Pension Growth’

The non-availability of foreign index bond is impeding desired...

Presidential Fiscal Policy Committee Proposes 8 Single Digit Taxes

Mr. Taiwo Oyedele Chairman The Presidential Fiscal Policy and Tax Reforms...

Wabote, Jonathan, Lumumba Win African Heritage Awards

  It was a night of colourful display of African...

Royal Exchange General Insurance Names Agili as New CEO

The Board of Directors of Royal Exchange Plc, has...
spot_img

Related Articles

Popular Categories

spot_imgspot_img